The AstraZeneca share price is rising fast. Here’s what I’d do now

FTSE 100 pharmaceuticals giant AstraZeneca turned in a good set of results. Is it time to buy right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceuticals giant AstraZeneca (LSE: AZN) share price was a big gainer yesterday, rising by 5.5% from the day before as it reported a healthy set of results. Its share price is now close to all-time highs, raising the question – Is this a good time to buy AZN?

Expensive but worthy

I find it helpful to look at the price-to-earnings ratio (P/E) when share prices are rising to get a sense of how expensive the stock really is. From the looks of it, AZN sure is highly priced. Its 12-month trailing P/E is almost 43x compared to 19x for another FTSE 100 pharmaceuticals peer GlaxoSmithKline (GSK). Not to undermine GSK’s value, but I think this is a case of investors putting a premium on AZN rather than a one-off spike in its P/E, considering that it’s been maintained for some time now.

It was my top share for May, after it reported a good set of numbers and my sense was that it would rise from there on. From the time the article was published to now, the share price is up 31% and interestingly enough, the P/E is actually marginally lower than the 45x seen then. As an investor, this tells me that there are capital gains to be made even if the ratio is high, instructive as it is. Also, a high ratio doesn’t indicate that the share price will come off soon. In other words, don’t let a high P/E deter you right now because there are enough reasons that still make AZN attractive.  

Safe haven

It’s a big pharmaceuticals company in an economic environment that continues to look uncertain. A number of other defensive shares have also seen a great run-up in share prices in recent years and AZN is no exception. Its international focus also helps, since it’s not entirely vulnerable to the UK’s fortunes. In the latest earnings release, CEO Pascal Soriot noted “impressive results” in international markets like China, the US and Japan.

Performance boost

Besides this, yesterday’s results showed an 18% increase in product sales at constant exchange rate and core operating profit grew by 41% in the third quarter of 2019. The numbers look good on a year-to-date basis too. I also like that AZN has actually upgraded its sales guidance for the second straight quarter, which basically means that it is expected to continue performing going forward.

Coming back to the original question – should I buy AZN shares now, even with the price rise? I reckon that its share price will rise higher over time if things continue to go the way they are right now. Since we at the Motley Fool are concerned with long-term investments, now is as good a time as any other to buy the share. As is the nature of share prices, there will most likely be short-term dips in the near future, and that should be an opportunity to buy more of AZN. But some can be bought right away, I believe.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

What on earth’s going to happen to the BP share price in 2026?

Harvey Jones looks at how the BP share price is shaping up for the year ahead, and finds investors have…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Have a £20,000 lump sum? Here’s how to target a £8,667 yearly passive income

How to turn £20,000 into a £8,667 passive income? Our Foolish author explains one counterintuitive strategy to build such an…

Read more »

British coins and bank notes scattered on a surface
Dividend Shares

2 dividend stocks that yield double the current UK interest rate

Following the latest UK interest rate cut, Jon Smith points out a couple of options that offer generous income relative…

Read more »

Investing Articles

A 9% yield and now this! Check out the stunning Taylor Wimpey share price forecast for 2026

Harvey Jones has kept the faith in Taylor Wimpey shares despite a difficult run, bolstered by their incredible yield. Next…

Read more »

Investing Articles

How much do you need in an ISA to aim for a life-changing passive income of £30,000 a year?

Harvey Jones says ISA savers can transform their futures in 2026 by investing in FTSE 100 dividend stocks with huge…

Read more »

Investing Articles

My top 10 ISA and SIPP stocks in 2026

Find out why a FTSE 100 investment trust is now this writer's top holding across his Stocks and Shares ISA…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

£10,000 invested in Rolls-Royce shares 5 Christmases ago is now worth…

James Beard reflects on the post-pandemic Rolls-Royce share price rally and whether the group could become the UK’s most valuable…

Read more »

Investing Articles

Will Nvidia shares continue their epic run into 2026 and beyond?

Nvidia shares have an aura of invincibility as an AI boom continues to benefit the chipmaker. Can anything stop the…

Read more »